Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression | Zendy

Xiaoran Wang | Zendy; Bowen Wang | Zendy; Na Zhao | Zendy; Chenjie Wang | Zendy; Mi Huang | Zendy; Baoxin Chen | Zendy; Jieping Chen | Zendy; Yan Sun | Zendy; Lang Xiong | Zendy; Shan Huang | Zendy; Yizhi Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression

Author(s) -

Xiaoran Wang,

Bowen Wang,

Na Zhao,

Chenjie Wang,

Mi Huang,

Baoxin Chen,

Jieping Chen,

Yan Sun,

Lang Xiong,

Shan Huang,

Yizhi Liu

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.19-27596

Subject(s) - downregulation and upregulation , fibronectin , epithelial–mesenchymal transition , gene knockdown , bromodomain , chemistry , cancer research , cell migration , microbiology and biotechnology , transforming growth factor , fibrosis , biology , cell , cell culture , pathology , medicine , extracellular matrix , histone , gene , biochemistry , genetics

Lens fibrosis involves aberrant growth, migration, and transforming growth factorβ (TGFβ)-induced epithelial-mesenchymal transition (EMT) of lens epithelial cells (LECs). In this study, we investigated the role of the bromo- and extra-terminal domain (BET) inhibitor in lens fibrotic disorder to identify drug-based therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research